[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP2493918A4 - Improved neurturin molecules - Google Patents

Improved neurturin molecules

Info

Publication number
EP2493918A4
EP2493918A4 EP10827453.1A EP10827453A EP2493918A4 EP 2493918 A4 EP2493918 A4 EP 2493918A4 EP 10827453 A EP10827453 A EP 10827453A EP 2493918 A4 EP2493918 A4 EP 2493918A4
Authority
EP
European Patent Office
Prior art keywords
molecules
improved neurturin
improved
neurturin molecules
neurturin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10827453.1A
Other languages
German (de)
French (fr)
Other versions
EP2493918A2 (en
Inventor
Pia Runeberg-Roos
Maxim Bespalov
Richard Penn
Mart Saarma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTF Therapeutics Inc
Original Assignee
NTF Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NTF Therapeutics Inc filed Critical NTF Therapeutics Inc
Priority to EP14165977.1A priority Critical patent/EP2774935B8/en
Publication of EP2493918A2 publication Critical patent/EP2493918A2/en
Publication of EP2493918A4 publication Critical patent/EP2493918A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
EP10827453.1A 2009-10-30 2010-10-28 Improved neurturin molecules Withdrawn EP2493918A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14165977.1A EP2774935B8 (en) 2009-10-30 2010-10-28 Improved neurturin molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25635209P 2009-10-30 2009-10-30
PCT/US2010/054419 WO2011053675A2 (en) 2009-10-30 2010-10-28 Improved neurturin molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP14165977.1A Division EP2774935B8 (en) 2009-10-30 2010-10-28 Improved neurturin molecules

Publications (2)

Publication Number Publication Date
EP2493918A2 EP2493918A2 (en) 2012-09-05
EP2493918A4 true EP2493918A4 (en) 2013-04-10

Family

ID=43922977

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10827453.1A Withdrawn EP2493918A4 (en) 2009-10-30 2010-10-28 Improved neurturin molecules
EP14165977.1A Active EP2774935B8 (en) 2009-10-30 2010-10-28 Improved neurturin molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14165977.1A Active EP2774935B8 (en) 2009-10-30 2010-10-28 Improved neurturin molecules

Country Status (9)

Country Link
EP (2) EP2493918A4 (en)
JP (1) JP2013509422A (en)
CN (1) CN102695723A (en)
AU (1) AU2010313456A1 (en)
BR (1) BR112012009801A8 (en)
CA (1) CA2778678A1 (en)
ES (1) ES2632431T3 (en)
NZ (1) NZ599543A (en)
WO (1) WO2011053675A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838818A1 (en) 2011-06-09 2012-12-13 University Of Miami Methods of treatment for retinal diseases
FR3093640B1 (en) * 2019-03-15 2021-10-01 Biophytis Phytoecdysones and their derivatives for their use in the treatment of neuromuscular diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008196A1 (en) * 1995-08-28 1997-03-06 Washington University Neurturin and related growth factors
WO2009059755A2 (en) * 2007-11-05 2009-05-14 Develogen Aktiengesellschaft Novel neurturin conjugates for pharmaceutical use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4409331A (en) 1979-03-28 1983-10-11 Damon Corporation Preparation of substances with encapsulated cells
US4542025A (en) 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US4829000A (en) 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5110596A (en) 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
AU5741590A (en) 1989-05-04 1990-11-29 Southern Research Institute Improved encapsulation process and products therefrom
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DE4137649C2 (en) 1991-11-15 1997-11-20 Gerhard Dingler Component
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
ATE163230T1 (en) 1993-03-09 1998-02-15 Epic Therapeutics Inc MACROMOLECULAR MICROPARTICLES AND METHOD FOR THE PRODUCTION THEREOF
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5554730A (en) 1993-03-09 1996-09-10 Middlesex Sciences, Inc. Method and kit for making a polysaccharide-protein conjugate
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
NL9401150A (en) 1994-07-12 1996-02-01 Nederland Ptt Method for presenting on a receiving side a first number of video signals originating from a transmitting side, as well as a system, as well as a transmitter, as well as a network, and also a receiver.
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2204789C (en) 1994-11-10 2002-11-12 Paul Ashton Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
ES2232713T3 (en) 1996-02-02 2005-06-01 Alza Corporation PROLONGED ADMINISTRATION OF AN ACTIVE AGENT USING AN IMPLANTABLE SYSTEM.
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US5976109A (en) 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
ATE252372T1 (en) 1996-08-23 2003-11-15 Sequus Pharm Inc LIPOSOMES CONTAINING CISPLATIN
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
JP2001503396A (en) 1996-10-11 2001-03-13 アルザ コーポレイション Therapeutic liposome compositions and methods
AU725257B2 (en) 1996-10-15 2000-10-12 Transave, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
US6395302B1 (en) 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
ES2231991T3 (en) 1997-06-11 2005-05-16 Borean Pharma A/S TRIMERIZATION MODULE.
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
ES2182379T3 (en) 1997-12-22 2003-03-01 Alza Corp MEMBRANE OF REGULATION OF THE LIBERATION REGIME FOR DEVICES OF CONTROLLED ADMINISTRATION OF PHARMACOS.
JP4494629B2 (en) 1997-12-30 2010-06-30 インターシア セラピューティクス，インコーポレイティド Beneficial agent supply system with membrane plug
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6283949B1 (en) 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
WO2002011778A1 (en) 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
AU2001284982A1 (en) 2000-08-15 2002-02-25 Board Of Trustees Of The University Of Illinois Method of forming microparticles
FR2814642B1 (en) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En TRANSGENIC MOUSE FOR THE TARGETED RECOMBINATION MEDIATED BY THE MODIFIED CRE-ER
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
CN1114690C (en) 2001-05-15 2003-07-16 乔良 Papilloma pseudovirus and process for preparing same
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
KR20060095568A (en) * 2003-10-20 2006-08-31 엔에스진 에이/에스 In vivo gene therapy of parkinson's disease
ATE435026T1 (en) * 2003-11-27 2009-07-15 Develogen Ag METHOD FOR PREVENTION AND TREATMENT OF DIABETES USING NEURTURIN
AU2005247369A1 (en) 2004-05-10 2005-12-08 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US7790446B2 (en) 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
US8034572B2 (en) * 2006-08-30 2011-10-11 Mart Saarma Receptor for GDNF family ligands
AU2007310838A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008196A1 (en) * 1995-08-28 1997-03-06 Washington University Neurturin and related growth factors
WO2009059755A2 (en) * 2007-11-05 2009-05-14 Develogen Aktiengesellschaft Novel neurturin conjugates for pharmaceutical use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAMILTON J F ET AL: "Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 168, no. 1, 1 March 2001 (2001-03-01), pages 155 - 161, XP002409643, ISSN: 0014-4886, DOI: 10.1006/EXNR.2000.7571 *
HILEMAN R E ET AL: "Glycosaminoglycan-protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins", BIOESSAYS, JOHN WILEY & SONS LTD, GB, vol. 20, no. 2, 1 February 1998 (1998-02-01), pages 156 - 167, XP002276571, ISSN: 0265-9247, DOI: 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.0.CO;2-R *
PILTONEN M ET AL: "Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 219, no. 2, 1 October 2009 (2009-10-01), pages 499 - 506, XP026583797, ISSN: 0014-4886, [retrieved on 20090715], DOI: 10.1016/J.EXPNEUROL.2009.07.002 *
See also references of WO2011053675A2 *

Also Published As

Publication number Publication date
BR112012009801A8 (en) 2016-08-30
WO2011053675A2 (en) 2011-05-05
ES2632431T3 (en) 2017-09-13
CN102695723A (en) 2012-09-26
NZ599543A (en) 2014-02-28
JP2013509422A (en) 2013-03-14
CA2778678A1 (en) 2011-05-05
EP2774935B1 (en) 2017-04-19
WO2011053675A3 (en) 2011-08-25
BR112012009801A2 (en) 2016-08-09
AU2010313456A1 (en) 2012-05-17
EP2493918A2 (en) 2012-09-05
EP2774935A1 (en) 2014-09-10
EP2774935B8 (en) 2017-06-21

Similar Documents

Publication Publication Date Title
IL218544A0 (en) Dll4-binding molecules
GB0815109D0 (en) Polydialkylsiloxane-bridged bi-photochromic molecules
GB0913011D0 (en) Graphene
EP2457176A4 (en) Virtual-machine-based application-service provision
GB201103481D0 (en) No details
GB201016096D0 (en) No details
PT2403845E (en) Improved process
GB201016097D0 (en) No details
GB0901254D0 (en) Process
PL2464939T3 (en) Improved workpiece-carrier
GB0914596D0 (en) Improved hatchcover
EP2453284A4 (en) Microscope
GB0905998D0 (en) Process
GB0914338D0 (en) Improved process
GB0901817D0 (en) Process
GB0902286D0 (en) Process
GB0901816D0 (en) Process
GB0900191D0 (en) Microscopy
GB201007492D0 (en) Microscope
GB0906031D0 (en) Process
GB0903956D0 (en) Process
EP2493918A4 (en) Improved neurturin molecules
GB0901822D0 (en) Process
GB0903562D0 (en) RNA molecules
GB0913782D0 (en) Microscope

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120430

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CNS THERAPEUTICS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NTF THERAPEUTICS, INC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130308

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20130304BHEP

Ipc: C07K 14/475 20060101ALI20130304BHEP

Ipc: C07K 14/47 20060101AFI20130304BHEP

Ipc: A61K 38/17 20060101ALI20130304BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PENN, RICHARD

Inventor name: SAARMA, MART

Inventor name: RUNEBERG-ROOS, PIA

Inventor name: BESPALOV, MAXIM

17Q First examination report despatched

Effective date: 20140131

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140813

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141224